Neurodevelopmental Disorders: Clinical Trials

3 trials for Neurodevelopmental Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 enrolling by invitation. 3 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33Enrolling by invitation 3
Phase 21Enrolling by invitation 1

Follow Neurodevelopmental Disorders: new trials by email Literature Review of Neurodevelopmental Disorders trials Research Report on Neurodevelopmental Disorders

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
Solriamfetol - ADHD
Phase 3Enrolling by invitationAxsome Therapeutics, Inc.3002026-08-062026-11-06
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
LP352 - Developmental and Epileptic Encephalopathy
Phase 3Enrolling by invitationLongboard Pharmaceuticals3242025-02-122026-10-14
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label
N-acetylcysteine - Autism Spectrum Disorder
Phase 2 / Phase 3Enrolling by invitationStanford University1442024-03-122026-05-15

Narrower conditions

Attention Deficit Disorder with Hyperactivity (1)  ·  Autism Spectrum Disorder (1)  ·  Epilepsies, Myoclonic (1)  ·  Epilepsy (1)  ·  Lennox Gastaut Syndrome (1)  ·  Seizures (1)

Broader conditions

Mental Disorders (3)  ·  Attention Deficit and Disruptive Behavior Disorders (1)  ·  Brain Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Child Development Disorders, Pervasive (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Epilepsy, Generalized (1)  ·  Epileptic Syndromes (1)  ·  Genetic Diseases, Inborn (1)  ·  Nervous System Diseases (1)  ·  Neurologic Manifestations (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Signs and Symptoms (1)

Interventions

Acetylcysteine (1)  ·  solriamfetol (1)

Sponsors

Axsome Therapeutics, Inc. (1)  ·  Longboard Pharmaceuticals (1)  ·  Stanford University (1)

Countries

United States (3)  ·  Australia (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Canada (1)  ·  China (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Japan (1)  ·  Latvia (1)  ·  Mexico (1)  ·  Netherlands (1)  ·  Portugal (1)  ·  Serbia (1)

Top investigators

John Hegarty, PhD (1)

NIH funding

K99HD101702 (1)